Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sonidegib Phosphate

FDA-approved product (capsule, oral), marketed as Odomzo.

Registered studies
2
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Sonidegib Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Basal cell carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hedgehog pathway inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sonidegib Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sonidegib Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

    NCT06880848 · start 2023-06-21

    Registered record
    Registry ID
    NCT06880848
    Conditions
    Carcinoma, Basal Cell (BCC)
    Interventions
    Sonidegib Phosphate Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-06-21
    Completion
    2025-08-26
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Basal Cell (BCC)
    InterventionSonidegib Phosphate Capsules
    PhasePhase 4
    Registry statusCompleted

  • Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

    NCT02303041 · start 2015-02

    Registered record
    Registry ID
    NCT02303041
    Conditions
    Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome
    Interventions
    Buparlisib; Sonidegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-02
    Completion
    2017-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome
    InterventionBuparlisib; Sonidegib
    PhasePhase 2
    Registry statusTerminated